Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
Intuitive Surgical Q3 2026 Earnings Analysis
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.
**JORDAN:** And I'm Jordan. Today we're diving into Intuitive Surgical's Q3 2026 results — the robotic surgery giant behind the da Vinci system.
**ALEX:** Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Good to have that out of the way. And Alex, this was a packed quarter — big numbers, a major legal settlement, pricing strategy shifts, even a new factory announcement in Malaysia.
**ALEX:** Let's start with the headline numbers. Revenue grew 22% year-over-year to just over $3 billion, with 84% of that being recurring revenue — which, as always, is the magic of Intuitive's razor-and-blade business model.
**JORDAN:** Right, and non-GAAP EPS grew 25% to $3 per share. Operating margin came in at 42%, or 41% if you strip out a one-time tariff refund. That's genuinely elite profitability for medtech.
**ALEX:** But here's the asterisk — GAAP net income actually fell to $523 million, down from $704 million a year ago. Why the disconnect?
**JORDAN:** That's the $450 million litigation settlement. Intuitive reached a no-fault agreement with customers in a class action lawsuit over third-party instrument remanufacturing and servicing. It's subject to court approval, expected sometime next year, but they took the charge now.
**ALEX:** So basically, they're paying to put a messy legal issue behind them and get certainty on how they work with hospitals going forward.
**JORDAN:** Exactly — CEO Dave Rosa framed it as removing a distraction so they can focus on advancing product safety and quality rather than litigating.
**ALEX:** Let's talk procedures, because that's really the heartbeat of this business. Total procedures grew 15%, da Vinci procedures up 14%, and Ion — that's their lung biopsy platform — up a blazing 31%.
**JORDAN:** The geographic split is interesting too. International da Vinci growth was 20%, while U.S. growth was 10% — and that 10% actually drew some pointed analyst questions on the call.
**ALEX:** Yeah, an analyst from Wells Fargo flagged that 10% as the slowest U.S. growth since COVID. What was management's response?
**JORDAN:** Dave Rosa basically said: don't panic, it's a tough comp — last year's Q3 grew 16%, their hardest comparison of the year. CFO Jamie Samath added more color, saying they're leaning into four growth levers: adding system capacity, especially for benign general surgery; pushing into ambulatory surgery centers, where ASC placements doubled over just two quarters; developing cardiac and breast procedures as emerging categories; and new indications in the R&D pipeline.
**ALEX:** And speaking of placements — system placements overall were strong. 546 da Vinci systems placed globally, up 28%. The da Vinci 5, their newest platform, now makes up 65% of global placements combined with the single-port system.
**JORDAN:** They've crossed 2,000 da Vinci 5 systems installed worldwide, used by over 18,000 surgeons. That's real traction for a platform that's still relatively new.
**ALEX:** Now let's get into the pricing story, because this is a genuine strategic shift. Intuitive announced they're cutting instrument pricing on high-volume "benign" procedures — think hernia repairs, gallbladder removals, hysterectomies — stuff where laparoscopy has dominated because it's cheaper.
**JORDAN:** They're extending the useful life of certain instruments and introducing volume-based pricing starting in 2027. The expected impact is a 3% to 5% reduction in da Vinci instrument-and-accessory revenue per procedure once fully rolled out.
**ALEX:** That sounds l
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet